GTAM
BMY.RT

Global Trust Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Global Trust Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,422
Closed -$2K – 446
2020
Q4 		$2K Buy
3,422
+1,722
+101% +$3.67K ﹤0.01% 368
2020
Q3 		$4K Buy
+1,700
New +$4.86K ﹤0.01% 309

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Global Trust Asset Management's BMY.RT Position: Q1 2021 in Review

Global Trust Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 3,422 shares — an estimated $2K sold.

Global Trust Asset Management first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $4K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Global Trust Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Global Trust Asset Management sold 3,422 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $2K.
  • Global Trust Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Global Trust Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Global Trust Asset Management's 13F filing for Q1 2021, filed 14 Apr 2021.